Janssen-Cilag

Janssen-Cilag is the Germany-focused pharmaceutical business operating under the Janssen name and associated with Janssen Pharmaceuticals, part of Johnson & Johnson. Its role is to provide prescription medicines and related pharmaceutical products in the German market, rather than to function as a standalone publicly listed company. The available reference material does not establish a separate founding year, founder, headquarters address, or distinct corporate financial profile for the German Janssen-Cilag entity. The brand reflects the combination of two important pharmaceutical histories within Johnson & Johnson. Janssen Pharmaceuticals was founded in Belgium in 1953 by scientist Paul Janssen and became part of Johnson & Johnson in 1961. Cilag Chemie also joined Johnson & Johnson in 1961. The two names subsequently became associated in several national pharmaceutical operations, including the German Janssen-Cilag business. This structure gives the German organization access to the research, development, manufacturing, regulatory, and commercial resources of the wider Johnson & Johnson pharmaceutical network. Janssen-Cilag’s business scope is centered on prescription medicines. The supplied material identifies major Janssen-related products and developments elsewhere in the Johnson & Johnson organization, including Prezista, a protease inhibitor launched in 2006 for people with HIV whose prior therapies had failed, and Spravato, the brand used for Janssen’s esketamine treatment for severe depression after regulatory approval in 2019. These products are associated with the broader Janssen pharmaceutical organization; the available sources do not confirm which products are specifically marketed by the German Janssen-Cilag legal or commercial entity, so they are not presented as a definitive German product catalogue. The German operation’s positioning can therefore be described as innovation-oriented prescription pharmaceuticals supplied through the German healthcare system. Its activities are likely shaped by national medical, regulatory, reimbursement, and pharmacovigilance requirements, but the supplied references do not provide enough entity-specific information to document its exact therapeutic-area portfolio, sales organization, manufacturing footprint, or current leadership. Janssen-Cilag should consequently be distinguished from Janssen Pharmaceuticals as a global business and from Johnson & Johnson as the ultimate parent group. The subject of this dossier is the Germany-specific Janssen-Cilag entity identified by the authoritative Wikipedia path, not the broader international Janssen brand.

Janssen-Cilag belongs to the international pharmaceutical network formed around Janssen Pharmaceuticals, Cilag, and Johnson & Johnson. The underlying Janssen history began in Belgium in 1953, when scientist Paul Janssen established Janssen Pharmaceuticals. The company developed a research-driven pharmaceutical identity and became known for medicines in several specialized therapeutic areas. Johnson & Johnson acquired Janssen Pharmaceuticals in 1961, bringing the Belgian company into its expanding healthcare portfolio. Cilag Chemie also joined Johnson & Johnson in 1961. The integration of the Janssen and Cilag names in national markets produced Janssen-Cilag operations, including the German business covered by this dossier. The available reference material does not specify the exact incorporation date of Janssen-Cilag in Germany, its original legal form, or the location from which it initially operated. Accordingly, the German entity’s early corporate history cannot be separated confidently from the broader development of Janssen and Cilag within Johnson & Johnson. Following the Johnson & Johnson acquisitions, Janssen’s pharmaceutical capabilities became part of a larger multinational research and commercial system. This system supported the development and international distribution of prescription products. A cited example is Prezista, a protease inhibitor launched by Janssen in 2006 for patients with HIV who had experienced failure of previous therapies. Another is Spravato, the Janssen brand for esketamine, which received United States regulatory approval in 2019 for severe depression. These developments illustrate the research-oriented profile associated with the Janssen organization, although the supplied material does not establish the precise German launch or reimbursement history of either product. In Germany, Janssen-Cilag operates as a national pharmaceutical business rather than as an independently listed group. Its commercial role is to make relevant prescription therapies available within the German healthcare environment, subject to national regulatory, medical, reimbursement, and safety requirements. The ultimate parent, Johnson & Johnson, is a diversified American healthcare corporation whose activities span pharmaceuticals, biotechnology, and medical technologies. Janssen-Cilag therefore benefits from a group structure that links national commercial operations with global research, development, manufacturing, and regulatory functions. The available sources do not provide a detailed chronology of German milestones, named executives, campaigns, scandals, acquisitions, or entity-specific financial results. They also do not identify a standalone stock listing or ticker for Janssen-Cilag. The documented history is consequently best understood as the history of a German Janssen-Cilag pharmaceutical operation within the broader Janssen and Johnson & Johnson development, while avoiding unsupported claims about the local entity’s exact founding, leadership, product approvals, or current organizational structure.

• 2019

  Spravato receives regulatory approval

  [1]Johnson & Johnsonen.wikipedia.org

  The United States Food and Drug Administration approved esketamine for severe depression; Janssen markets the treatment under the Spravato name. The source does not establish the German Janssen-Cilag approval or launch timeline.

• 2006

  Janssen launches Prezista

  [1]Johnson & Johnsonen.wikipedia.org

  Janssen launched Prezista, a protease inhibitor for HIV patients whose previous therapies had failed. The available source describes this as a broader Janssen development and does not confirm a specific German launch date.

• 1961

  Janssen Pharmaceuticals acquired by Johnson & Johnson

  [1]Johnson & Johnsonen.wikipedia.org

  Johnson & Johnson acquired Janssen Pharmaceuticals, bringing the Belgian pharmaceutical company into its multinational healthcare group.

• 1961

  Cilag joins Johnson & Johnson

  [1]Johnson & Johnsonen.wikipedia.org

  Cilag Chemie joined Johnson & Johnson, creating the corporate background from which Janssen-Cilag national operations developed.

• 1953

  Janssen Pharmaceuticals founded

  [1]Johnson & Johnsonen.wikipedia.org

  Paul Janssen founded Janssen Pharmaceuticals in Belgium, establishing the pharmaceutical organization that later became part of Johnson & Johnson.

Innovation-oriented prescription pharmaceuticals supplied to the German healthcare market.

• Pharmaceuticals

  Prescription medicines

  Janssen-Cilag is principally associated with prescription pharmaceutical products supplied through the German healthcare market. The available reference material does not provide a verified, entity-specific catalogue of brands, therapeutic areas, or current products, so individual medicines are not attributed directly to the German business without confirmation.

• HIV medicine · 2006

  Prezista

  Prezista is a Janssen protease inhibitor developed for people with HIV whose earlier treatment regimens had failed. It demonstrates the broader Janssen organization’s involvement in infectious-disease medicines. The supplied reference does not confirm whether the German Janssen-Cilag entity currently markets the product or specify its German launch history.

• Mental-health medicine · 2019

  Spravato

  Spravato is the Janssen brand associated with esketamine for severe depression. The product received United States regulatory approval in 2019. The available reference material does not establish the German regulatory, reimbursement, or commercial status under Janssen-Cilag.

1. 1Johnson & Johnsonen.wikipedia.org
2. 2Janssen-Cilag official German websitejanssen-cilag.de